# Jonas Brambeck

> Jonas Brambeck is a funding round investor at Industrifonden backing Biotechnology and Health Care. See 4 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Industrifonden](https://shizune.co/investors/profile/industrifonden)
- Location: Stockholm, Sweden
- Total investments: 4
- Last investment: Nov 2016
- Lead investor: 25%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/jonas-brambeck-776a7b3

Jonas Brambeck is a funding round investor at Industrifonden in Stockholm focused on Biotechnology and Health Care. Jonas Brambeck is the Investment Manager of Life Science at ndustrifonden. Jonas joined Industrifonden in 1998 and has been part of a large number of investments, transactions and exits. Jonas serves on the Board of Directors of Cardoz, Oncopeptides, Oxthera och Nuevolution AS. Jonas, formerly a Nordic region manager for sale and marketingof analytical instruments at Bruker AB. Jonas earned Ph.D. in organic chemistry from The Royal Institute of Technology in Stockholm.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 3 | 75% |
| Health Care | 2 | 50% |
| Medical | 1 | 25% |
| Manufacturing | 1 | 25% |
| Pharmaceutical | 1 | 25% |

6 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Funding Round | 2 | 50% |
| Series A | 1 | 25% |
| Series D | 1 | 25% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| Sweden | 2 | 50% |
| Denmark | 1 | 25% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| OxThera | OxThera is a biopharmaceutical company with products in late stage clinical development focusing on Primary and Secondary Hyperoxaluria. OxThera’s intellectual property includes worldwide patents for compositions and treatment of hyperoxaluria with bacteria, and enzymes. Oxabact® holds Orphan Drug designations in Europe and in the US for thetreatment of primary hyperoxaluria. | $35.1M | Series D | Nov 29, 2016 |  |
| Nuevolution | Nuevolution is a leading small molecule lead discovery company founded in 2001 and based in Copenhagen, Denmark. The company has developed Chemetics®, a unique, patent protected hybrid of proven wet chemistry and molecular biology which represents the ultimate fragment based drug discovery technology. Chemetics® enables rapid synthesis andDNA-tagging of hundreds of millions of chemically diverse drug-like small molecule compounds and the efficient screening of these, facilitating the identification of potent drug leads at unprecedented quantity, quality and speed compared to existing drug discovery technologies. Nuevolutions library collection currently exceeds 1 billion small molecule compounds and synthetic biologics for screening. Nuevolution partners its technology with pharmaceutical and biotechnology companies. Nuevolution has entered into agreementswith Merck & Co., Lexicon Pharmaceuticals, GlaxoSmithKline, Novartis Pharma and Boehringer Ingelheim. Nuevolution has also entered into a joint venture consortium between Nuevolution, EpiTherapeutics, ExpreS2ion Biotechnologies and Professor Kristian Helin (Biotech Research & Innovation Centre, University of Copenhagen) aiming at discovery and development of novel small molecule drugs against epigenetic factors. This $ 4 million budget project is supported by the Danish High Technology Fund. Nuevolution has demonstrated the power of Chemetics® by identifying highly potent and drug like novel ligands with the potential toaddress major unmet medical needs across a range of therapeutic areas and target classes. Nuevolution is a privately owned company by key Scandinavian investors, including Industrifonden, SEB Venture Capital, SunstoneCapital, SLS Invest and Novo A/S. | $12.1M |  | Jun 19, 2012 |  |
| Cardoz | Cardoz AB manufactures anti-inflammatory pharmaceuticals to combat heart and vascular disorders. The company was founded in 2006 and is based in Stockholm, Sweden. |  | Series A | Sep 16, 2010 |  |
| OxThera | OxThera is a biopharmaceutical company with products in late stage clinical development focusing on Primary and Secondary Hyperoxaluria. OxThera’s intellectual property includes worldwide patents for compositions and treatment of hyperoxaluria with bacteria, and enzymes. Oxabact® holds Orphan Drug designations in Europe and in the US for thetreatment of primary hyperoxaluria. | $14.5M |  | Jun 29, 2007 |  |

4 of 4 investments shown.

## Co-investors
- [HealthCap](https://shizune.co/investors/profile/healthcap) — VC Fund, 2 deals together
- [Sunstone Life Science Ventures](https://shizune.co/investors/profile/sunstone-capital-life-science) — VC Fund, 2 deals together
- [Ysios Capital](https://shizune.co/investors/profile/ysios-capital) — VC Fund, 2 deals together
- [Brohuvudet](https://shizune.co/investors/profile/brohuvudet) — VC Fund, 1 deal together
- [Flerie Invest](https://shizune.co/investors/profile/flerie-invest) — VC Fund, 1 deal together
- [Forbion Capital Partners](https://shizune.co/investors/profile/forbion-capital-partners) — VC Fund, 1 deal together

## About Industrifonden

VC Fund · Stockholm, Sweden

Industrifonden is a Nordic evergreen venture capital firm with a fund size of $600m, that focuses on early-stage technology and life science companies with international potential. The company works long term with the entrepreneurs we invest in, and have a strong track record of building game changing companies. Industrifonden-backed companiesinclude tech companies Qlik, Arcam, Soundtrack Your Brand, Fishbrain, and life science companies CellaVision, Oncopeptides and AMRA.

5 contacts available at Industrifonden.

| Name | Title | Profile |
| --- | --- | --- |
| Anna Ljungdahl | Investment Manager | https://shizune.co/investors/profile/anna-ljungdahl |
| Bita Sehat | Investment Manager of Life Science | https://shizune.co/investors/profile/bita-sehat |
| Hadar Cars | Senior Investment Director | https://shizune.co/investors/profile/hadar-cars |
| Hansson Lennart | Business Unit Manager Life Science | https://shizune.co/investors/profile/hansson-lennart |
| Jonas Brambeck | Investment Manager - Life Science | https://shizune.co/investors/profile/jonas-brambeck |

## Similar investors

### Similar stage
- [Bpifrance](https://shizune.co/investors/profile/bpifrance) — VC Fund
- [SFC Capital](https://shizune.co/investors/profile/startup-funding-club) — VC Fund
- [HTGF (High-Tech Gruenderfonds)](https://shizune.co/investors/profile/high-tech-gr%C3%BCnderfonds) — VC Fund

## FAQ

### What does Jonas Brambeck invest in?

Jonas Brambeck invests primarily in Biotechnology, Health Care and Medical startups, most often at Funding Round and Series A stage. Most of the 4 investments tracked by Shizune back companies in Sweden. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Jonas Brambeck last invest?

The most recent investment recorded for Jonas Brambeck closed in Nov 2016. Shizune tracks 4 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co